April 19, 2016
Exclusion criteria in studies of direct-acting antivirals (DAAs) for hepatitis C (HCV) infection would have kept high proportions of HCV/HIV-coinfected individuals out of those studies, according to analysis of eligibility for five trials by members of the Canadian Coinfection Cohort. The most frequent exclusion criteria ruled out certain antiretroviral combinations or active illicit drug use.
DAAs revolutionized treatment of HCV infection, typically curing more than 90% of participants in controlled trials. Sustained virologic response (SVR) rates have also been high in HCV patients coinfected with HIV. But because most trials exclude certain subgroups, it remains unclear whether these good results with DAAs apply to most coinfected people with HIV infection.
To address that question, researchers working with the Canadian Coinfection Cohort determined proportions of cohort members who would have been excluded from five large DAA efficacy trials that enrolled HCV/HIV-coinfected patients and tested diverse DAAs: NCT01479868 (simeprevir [TMC435]), PHOTON-1 (sofosbuvir [Sovaldi]), TURQUOISE-I (ombitasvir, paritaprevir/ritonavir/dasabuvir [Viekira Pak]), ION-4 (sofosbuvir/ledipasvir [Harvoni]) and ALLY-2 (daclatasvir [Daklinza] + sofosbuvir [Sovaldi]). Up to April 1, 2015, the Canadian Coinfection Cohort had enrolled 1423 coinfected people at 18 centers. After excluding people who died or dropped out of the cohort and people with genotypes not reflecting trial populations, the researchers had 615 patients with evidence of chronic HCV infection.
Trial eligibility criteria would have excluded all but 5.9% of cohort members (24 of 410) from NCT01479868, 9.8% (52 of 530) from PHOTON-1, 6.3% (26 or 410) from TURQUOISE-I and 8.1% (34 or 421) from ION-4. In contrast, 43% of cohort members (233 of 541) would have been eligible for the more inclusive ALLY-2 trial.
In the four more exclusionary trials, the most frequent exclusion criteria were restriction to specific antiretrovirals (excluding from 63% to 79% of the Canadian Coinfection Cohort) and active illicit drug use (excluding 53% to 55%). Even if cohort members could have safely switched to acceptable antiretroviral regimens, the four more exclusionary trials would have barred 74% to 77% from screening, largely because of active illicit drug use. Less frequent exclusion criteria included detectable HIV RNA (15% to 18% excluded) and minimal CD4+ counts (3% to 19% excluded).
Because these five DAA trials would have excluded most HCV/HIV-coinfected people in the Canadian cohort, the researchers conclude that these "trial results may have limited generalizability" to a wider HCV/HIV population. They determined "that the majority of exclusionary criteria were not related to safety but appear to be aimed at maximizing treatment response rates." The authors argue that exclusion of active drug users "may have been overly conservative as studies have shown they can achieve comparable SVRs as those not injecting drugs in well-supported settings." They call for observational studies to gauge DAA treatment response in coinfected populations "to determine how effective these therapies will be in the real world."
Mark Mascolini writes about HIV infection.
Copyright © 2016 Remedy Health Media, LLC. All rights reserved.
|Understanding the Magnitude of the Viral Hepatitis Epidemics in the United States|
|Helping Hepatitis C Patients Who Are Waiting for Treatment|
|New HCV Infection Rate Rising in HIV-Positive Gay or Bisexual Men|
No comments have been made.
The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.
|Separate and Unequal Access Frames Discussion at CROI Panel on U.S. HIV Care Cascade|
|CROI 2018: Highlights and What's Next for Advocates|
|Reported PrEP 'Failure' Most Likely a Lack of Proper Testing and Adherence|
|Injection Drug Use Among People Living With HIV: A Missed Opportunity to Save Lives|
|Statin Use Might Reduce Risk of Cancer in HIV-Positive People|
|Insurers and Pharmas Must Help Fix HIV Drug Pricing System, Advocates Say|